Silver Spring, Maryland—(ENEWSPF)—November 22, 2013. The U.S. Food and Drug Administration today expanded the approved uses of Nexavar (sorafenib) to treat late-stage (metastatic) differentiated thyroid cancer.
FDA Approves Nexavar to Treat Type of Thyroid Cancer
More in Health and Fitness:
